Elucid Bioimaging, Inc. Announces Opening of Enrollment in the Q-CAMP study at LSU Medical Center in New Orleans, LA – August 8, 2014
Elucid Bioimaging, Inc., a specialty Contract Research Organization (CRO) and leader in quantitative image analysis services, is pleased to report the opening of enrollment in the Q-CAMP, Quantitative CArdiovascular Magnetic Resonance Imaging and Profiling of Atherosclerotic Lesions, Study (Clinicaltrial.gov study number NCT02143102) being conducted at the Interim Louisiana State University Hospital in New Orleans, LA.
The 150 patient, observational study will use MRI and Elucid’s vascuCAP™ software analysis program to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an endarterectomy of the aforementioned vascular beds as part of their routine clinical care. In the first 75 patients, the endarterectomy specimens removed at surgery will allow a direct comparison between the MRI information obtained prior to the surgery and the histopathological analyses of the arterial specimens in order to further develop the vascuCAP™ analysis program. The vascuCAP™ data from the second group of patients will be compared in a blinded fashion with the histology to assess performance of plaque profiling and to build a pilot prediction model for risk scoring.
Elucid Bioimaging Inc. is a specialty CRO and leader in quantitative image analysis services to characterize, optimize, and validate imaging biomarkers for drug development to improve the effectiveness and reduce the cost of clinical trials of novel therapies and develop improved tools for medical decisions and patient management.